NCT01709461Unknown不适用
Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 12
- 试验地点
- 1
研究概览
简要总结
the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •subjects who are willing to contiue this treatment.
- •subjects who took part in the TVP 1012/501 clinical trail.
排除标准
- •subjects who didn't take part in the TVP 1012/501 clinical trail.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical TrialParkinson DiseaseNCT01851850Rabin Medical Center1
已完成
2 期
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabMultiple MyelomaNCT02719613Bristol-Myers Squibb67
已完成
2 期
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating DasatinibMultiple Indications CancerNCT02297139Bristol-Myers Squibb17
已完成
2 期
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCancerNCT04125693Bayer1
招募中
3 期
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyCancerNCT05862285Hoffmann-La Roche100